Recombinant Factor VIII Concentrates

ABSTRACT

The development and introduction of recombinant factor VIII (rFVIII) concentrates nearly 20 years ago represented a major advance in the treatment of hemophilia A patients. Currently, first-, second- and third-generation rFVIII products are commercially available. Whereas first-generation rFVIII concentrates are stabilized with human albumin, second-generation rFVIII products contain sucrose instead of albumin in the final formulation. Finally, third-generation rFVIII products are manufactured without additional human or animal plasma proteins. The use of rFVIII concentrates has greatly improved the safety of replacement therapy in hemophilia A and virtually abolished the risk of blood-borne pathogen transmission. The remaining and most challenging aspect of hemophilia A management has now become the development of FVIII inhibitors. In this article we review the current knowledge on the commercially available rFVIII concentrates, analyzing their main characteristics. Moreover, results of the literature on their clinical hemostatic efficacy and safety are summarized.

KEYWORDS

rFVIII - bleeding - hemophilia - inhibitors

REFERENCES

• 1 Kasper C K. Concentrate safety and efficacy.  Haemophilia. 2002;  8(T3) 161-165
• 2 Mannucci P M, Tuddenham E G. The hemophilias—from royal genes to gene therapy.  N Engl J Med. 2001;  344(23) 1773-1779
• 3 Leissinger C A. Prophylaxis in haemophilia patients with inhibitors.  Haemophilia. 2006;  12(Suppl 6) 67-72 discussion 72-73
• 4 Toole J J, Knopf J L, Wozney J M et al.. Molecular cloning of a cDNA encoding human antihaemophilic factor.  Nature. 1984;  312(5992) 342-347
• 5 Pipe S W. Recombinant clotting factors.  Thromb Haemost. 2008;  99(5) 840-850
• 6 Josephson C D, Abshire T. The new albumin-free recombinant factor VIII concentrates for treatment of hemophilia: do they represent an actual incremental improvement?.  Clin Adv Hematol Oncol. 2004;  2(7) 441-446
• 7 Lusher J M, Scharrer I. Evolution of recombinant factor VIII safety: KOGENATE and Kogenate FS/Bayer.  Int J Hematol. 2009;  90(4) 446-454
• 8 Musso R. Efficacy and safety of recombinant factor VIII products in patients with hemophilia A.  Drugs Today (Barc). 2008;  44(10) 735-750
• 9 Lippi G, Franchini M, Favaloro E J. One-stage clotting versus chromogenic assays for assessing recombinant factor VIII: two faces of a haemostasis coin.  Blood Coagul Fibrinolysis. 2009;  20 1-3
• 10 Ingerslev J, Jankowski M A, Weston S B, Charles L A. ReFacto Field Study Participants . Collaborative field study on the utility of a BDD factor VIII concentrate standard in the estimation of BDDr factor VIII:C activity in hemophilic plasma using one-stage clotting assays.  J Thromb Haemost. 2004;  2(4) 623-628
• 11 Pipe S. Antihemophilic factor (recombinant) plasma/albumin-free method for the management and prevention of bleeding episodes in patients with hemophilia A.  Biologics. 2009;  3 117-125
• 12 Dargaud Y, Negrier C. Haemophilia therapies.  Expert Opin Biol Ther. 2007;  7(5) 651-663
• 13 Farrugia A. Evolving perspectives in product safety for haemophilia.  Haemophilia. 2002;  8(3) 236-243
• 14 Schimpf K. On the way to virus-safe blood coagulation factor concentrates.  Semin Thromb Hemost. 2002;  28(suppl 1) 15-24
• 15 Tagliaferri A, Rivolta G F, Iorio A et al.. Mortality and causes of death in Italian persons with haemophilia, 1990–2007.  Haemophilia. 2010;  , February 9 (Epub ahead of print)
• 16 Bray G L, Gomperts E D, Courter S The Recombinate Study Group et al. A multicenter study of recombinant factor VIII (Recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A.  Blood. 1994;  83(9) 2428-2435
• 17 White II G C, Courter S, Bray G L, Lee M, Gomperts E D. The Recombinate Previously Treated Patient Study Group . A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A.  Thromb Haemost. 1997;  77(4) 660-667
• 18 Abshire T C, Brackmann H H, Scharrer I et al.. Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy—International Kogenate-FS Study Group.  Thromb Haemost. 2000;  83(6) 811-816
• 19 Lusher J M, Lee C A, Kessler C M, Bedrosian C L. ReFacto Phase 3 Study Group . The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A.  Haemophilia. 2003;  9(1) 38-49
• 20 Tarantino M D, Collins P W, Hay C R RAHF-PFM Clinical Study Group et al. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A.  Haemophilia. 2004;  10(5) 428-437
• 21 Lusher J M. First and second generation recombinant factor VIII concentrates in previously untreated patients: recovery, safety, efficacy, and inhibitor development.  Semin Thromb Hemost. 2002;  28(3) 273-276
• 22 Kreuz W, Gill J C, Rothschild C International Kogenate-FS Study Group et al. Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: results of an international clinical investigation.  Thromb Haemost. 2005;  93(3) 457-467
• 23 Musso R, Santagostino E, Faradji A KOGENATE Bayer European PMS Study Group et al. Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting.  Thromb Haemost. 2008;  99(1) 52-58
• 24 Shi J, Zhao Y, Wu J, Sun J, Wang L, Yang R. Safety and efficacy of a sucrose-formulated recombinant factor VIII product for the treatment of previously treated patients with haemophilia A in China.  Haemophilia. 2007;  13(4) 351-356
• 25 Shapiro A, Gruppo R, Pabinger I et al.. Integrated analysis of safety and efficacy of a plasma- and albumin-free recombinant factor VIII (rAHF-PFM) from six clinical studies in patients with hemophilia A.  Expert Opin Biol Ther. 2009;  9(3) 273-283
• 26 Lusher J M. Is the incidence and prevalence of inhibitors greater with recombinant products? No.  J Thromb Haemost. 2004;  2(6) 863-865
• 27 Aledort L M. Is the incidence and prevalence of inhibitors greater with recombinant products? Yes.  J Thromb Haemost. 2004;  2(6) 861-862
• 28 Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review.  Haemophilia. 2003;  9(4) 418-435
• 29 Gouw S C, van den Berg H M. The multifactorial etiology of inhibitor development in hemophilia: genetics and environment.  Semin Thromb Hemost. 2009;  35(8) 723-734
• 30 Suzuki T, Arai M, Amano K, Kagawa K, Fukutake K. Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII complexed with von Willebrand factor.  Thromb Haemost. 1996;  76(5) 749-754
• 31 Bajwa N, Enriquez M M, Gorina E, Lemm G. Cumulative analysis of inhibitor formation in patients with haemophilia A treated with sucrose-formulated recombinant factor VIII.  Haemophilia. 2009;  15(2) 597-600
• 32 Scharrer I, Ehrlich H J. Lack of evidence for increased inhibitor incidence in patients switched from plasma-derived to recombinant factor VIII.  Haemophilia. 2001;  7 346-348
• 33 Goudemand J, Rothschild C, Demiguel V FVIII-LFB and Recombinant FVIII study groups et al. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A.  Blood. 2006;  107(1) 46-51
• 34 Chalmers E A, Brown S A, Keeling D Paediatric Working Party of UKHCDO et al. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A.  Haemophilia. 2007;  13(2) 149-155
• 35 Gouw S C, van der Bom J G, Auerswald G, Ettinghausen C E, Tedgård U, van den Berg H M. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study.  Blood. 2007;  109(11) 4693-4697
• 36 Ettingshausen C E, Kreuz W. Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development.  Haemophilia. 2006;  12(Suppl 6) 102-106
• 37 DiMichele D M, Hoots W K, Pipe S W, Rivard G E, Santagostino E. International workshop on immune tolerance induction: consensus recommendations.  Haemophilia. 2007;  13(Suppl 1) 1-22
• 38 Santagostino E, Mannucci P M, Bianchi Bonomi A. Guidelines on replacement therapy for haemophilia and inherited coagulation disorders in Italy.  Haemophilia. 2000;  6(1) 1-10
• 39 United Kingdom Haemophilia Centre Doctors' Organisation . Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders.  Haemophilia. 2003;  9(1) 1-23
• 40 Batlle J, Villar A, Liras A et al.. Consensus opinion for the selection and use of therapeutic products for the treatment of haemophilia in Spain.  Blood Coagul Fibrinolysis. 2008;  19(5) 333-340
• 41 Di Minno G, Cerbone A M, Coppola A et al.. Longer-acting factor VIII to overcome limitations in haemophilia management: the PEGylated liposomes formulation issue.  Haemophilia. 2010;  16(Suppl 1) 2-6
• 42 Chuah M K, Collen D, VandenDriessche T. Clinical gene transfer studies for hemophilia A.  Semin Thromb Hemost. 2004;  30(2) 249-256
• 43 Ragni M V. Hemophilia gene transfer: comparison with conventional protein replacement therapy.  Semin Thromb Hemost. 2004;  30(2) 239-247
• 44 Viiala N O, Larsen S R, Rasko J E. Gene therapy for hemophilia: clinical trials and technical tribulations.  Semin Thromb Hemost. 2009;  35(1) 81-92
• 45 Lippi G, Franchini M, Saenko E L. Gene therapy for hemophilia A. Friend or foe?.  Blood Coagul Fibrinolysis. 2009;  20(6) 395-399